UG Healthcare - Phillip Securities 2022-08-30: Downcycle Extended, But Valuations Attractive

UG HEALTHCARE CORPORATIONLTD (SGX:8K7)

UG Healthcare - Downcycle Extended, But Valuations Attractive

UG Healthcare (SGX:8K7)'s 4QFY22 PATMI was below expectations. FY22 Revenue and PATMI were 103%/93% of our FY22e forecasts. Glove selling prices remain sluggish, still inching lower on a q-o-q basis.
The largest drag in 4QFY22 was the higher operating expenses. UG Healthcare is building up a new sales team in Europe to focus on reusable heavy duty gloves. We expect higher costs in the coming quarters as the company builds a new distribution and brand in the region.

We cut our FY23e PATMI forecast for UG Healthcare by 39%. Our expectations are that stable glove prices are unlikely. Competition from China continues to depress nitrile glove prices globally. Demand is also affected by overstocking and slower demand post-pandemic. UG Healthcare’s strength is the ability to source low-priced gloves from other manufacturers for its trading business.
UG Healthcare's share price is still trading below book value with net cash of S$84mil.

Gross margins in 4Q22 improved on a q-o-q basis to 38%. We believe the trading business drove the bounce in margins. The offset was a doubling in minority interest.

There was an estimated 64% y-o-y (or S$4.8mil) jump rise in operating expenses in 4Q22. We believe that it was due to the additional headcount in Europe to build the reusable non-glove trading operations.

Production in 4Q22 was lower due to existing foreign workers returning home after the border reopened in Malaysia. Recruitment of new foreign workers has also turned slower due to additional social and ethical due diligence. The lack of workers has delayed the commencement of the new 1.2bn piece factory. Other challenges include new competition in key market Brazil as registration and market surveillance of gloves was relaxed.
UG Healthcare is looking to build a new business in reusable industrial gloves for the auto, construction and manufacturing industries. There will be an upfront cost to build the distribution and branding of these gloves.

We downgrade our recommendation on UG Healthcare from BUY to NEUTRAL and lower our target price for UG Healthcare from S$0.32 to S$0.20. The target price is pegged to a discount to the Big 4 glove makers or 5x FY22e P/E.
See

Paul Chew Phillip Securities Research | https://www.stocksbnb.com/ 2022-08-30

SGX Stock Analyst Report NEUTRAL DOWNGRADE BUY 0.20 DOWN 0.320